TScan Therapeutics Announces Strategic Reorganization and 75% Workforce Reduction

TScan Therapeutics, Inc. (TSCN) initiated a prioritization strategy to focus on its in vivo solid tumor program, pausing further enrollment in its Phase 3 ALLOHA-2™ study. This strategic reorganization includes a workforce reduction of approximately 75% and the termination of the Chief Financial Officer and Chief Medical Officer. The company expects to incur about $4.1 million in employee-related costs.